Science Corporation Raises $400M at $3.5B Value

The brain-chip company's PRIMA device is approved in Europe and is now pursuing a U.S. route through the FDA.

Updated on Nov. 17, 2026 in Biotech

Bold flat-color editorial illustration of a thin silicon implant disc with copper traces on a plinth, beside a small cluster of cultured nerve cells in a dish.
Science Corporation raised $400 million in a Series D round valuing the brain-chip company at $3.5 billion, as its PRIMA device wins approval in Europe. AI Illustration. Upload story photo >

Live Poll

Would you trust a brain implant to treat a serious medical condition?

Science Corporation, founded in 2021 by Max Hodak, raised a $400 million Series D round that was announced in a company blog post, with investors valuing the company at $3.5 billion according to a person familiar with the deal. The company's first product, PRIMA, a wearable and implantable chip, is approved in Europe and available in Germany, while its U.S. path is still in progress. This is a funding and valuation announcement; the reported development is shipped in Europe, while the planned U.S. path and the bio-hybrid sensor remain announced.

Why it matters

The round signals strong investor appetite for brain-computer interfaces moving from research toward commercial medical devices, with PRIMA already past regulatory approval in Europe. The company is pursuing a U.S. route through the FDA's Humanitarian Device Exemption, a pathway that is the next major test of whether its approach can reach American patients.

The funding is reported as a $400 million Series D, with the $3.5 billion valuation disclosed by a person familiar with the deal rather than in a formal filing. The source gives no clinical performance figures for PRIMA or the bio-hybrid sensor, so the scale of the technical results remains unquantified.

The players

Science Corporation

A company founded in 2021 by Max Hodak that develops brain-computer interface devices, with its first product, PRIMA, approved in Europe.

Murat Günel

A Yale neurosurgery professor collaborating on the initial human trials of Science Corporation's bio-hybrid sensor.

The details

PRIMA is described as a wearable and implantable chip, and it is being trialled for Stargardt's disease, an inherited form of progressive vision loss. Science Corporation is seeking to bring PRIMA to the United States through the FDA's Humanitarian Device Exemption, a pathway for devices intended to treat rare conditions. The company is also designing initial human trials of a bio-hybrid sensor built from cultured neurons, which are living nerve cells grown in a lab, combined with silicon electronics, with Yale neurosurgery professor Murat Günel collaborating on those trials.

Timeline

  1. Science Corporation was founded in 2021 by Max Hodak.

  2. The Series D funding round and valuation were reported on November 17, 2026.

The Tech Race

The round places Science Corporation among companies pursuing implantable brain interfaces, with PRIMA already past European approval while rivals' products are not described in the source. The next competitive marker is whether the FDA Humanitarian Device Exemption route succeeds for PRIMA in the United States.

PRIMA is available today in Germany following its European approval, but it is not yet available in the United States, and the source gives no date for an FDA decision. The bio-hybrid sensor is still at the stage of trial design and has no reported availability or price.

The takeaway

The round suggests investors expect implantable neural devices to reach commercial scale, but the decisive milestone is an FDA decision on PRIMA through the Humanitarian Device Exemption, which the source does not date. Watch for the start of the initial human trials of the bio-hybrid sensor being designed with Yale's Murat Günel.

Further reading

For the broader research context, see the Biotech section.

Live Poll

Would you trust a brain implant to treat a serious medical condition?